Seikagaku Corporation Revises Earnings & Dividend Forecast Down Sharply

Seikagaku Corporation (TSE:4548), a pharmaceutical and biochemical products manufacturer, has revised its full-year earnings and dividend forecast for the fiscal year ending March 2027 downward, citing a significant decline in royalty income.

ItemBeforeAfterChange
RevenueJPY 41.9bnJPY 37.1bn-11.4%
Operating ProfitJPY 2.05bn-JPY 2.05bn
Ordinary IncomeJPY 4.20bnJPY 200M-95.2%
Net Profit (attributable to parent)JPY 2.25bn-JPY 1.80bn
EPSJPY 41.21/share-JPY 32.96/share

The company expects royalty revenue—a key earnings driver—to decline substantially, reducing full-year revenue to JPY 37.1bn from the previously forecast JPY 41.9bn, a contraction of 11.4%. The revenue shortfall cascades through the profit line: operating profit swings to a loss of JPY 2.05bn from an expected JPY 2.05bn gain, while ordinary income (keijo rieki), a Japan-specific metric that includes non-operating items, plummets 95.2% to JPY 200M. Net profit attributable to parent company shareholders is now projected at a loss of JPY 1.8bn, versus a prior forecast of JPY 2.25bn profit. Earnings per share turn negative at JPY -32.96/share.

In response to the earnings deterioration, Seikagaku has cut its annual dividend forecast by 33.3% to JPY 20.00/share from JPY 30.00/share, reducing shareholder returns materially. The revision underscores the company’s exposure to royalty-dependent revenue streams and signals operational headwinds ahead. Investors should monitor whether management provides further detail on the timing and duration of the royalty decline.

Separately, Seikagaku disclosed a new non-consolidated (parent-only) earnings forecast for FY2027, which it had not previously published; the company said the projected divergence from FY2026 actual results now meets its timely-disclosure threshold. On a non-consolidated basis, Seikagaku projects revenue of JPY 22.0bn (down 6.8% from FY2026 actual revenue of JPY 23.60bn), an operating loss of JPY 3.6bn, an ordinary loss of JPY 900M, a net loss of JPY 2.45bn, and EPS of JPY -44.86/share.


Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.